Rebleeding is a major complication in patients admitted for aneurysmal subarachnoid hemorrhage. The optimal timing for aneurysm securing after the initial headache remains debated. The objective of this study was to evaluate the previously established predictive factors for rebleeding in a contemporary retrospective cohort (2020-2022, Rennes University Hospital). Among the 226 patients included in the analysis, 33 (15%) experienced rebleeding. The mean time-to-event (rebleeding or securing) was significantly shorter in patients without rebleeding compared with patients with rebleeding (36 ± 3 vs. 63 ± 9 hours, respectively, p<0.001). For each additional hour of delay since the first symptoms, the odds of rebleeding increased by 0.7% (OR = 1.007 [1.001-1.013], p=0.026). This association remains significant in multivariate analysis. Despite its limitations, this study highlights the importance of early management, taking into account the time elapsed since the initial headache.

The authors have declared no competing interest.

No specific funding was received for this study.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Comité d’éthique, CHU Rennes, Hôpital Pontchaillou, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9, France; comite.ethiquechu-rennes.fr; +33299873553

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Available on reasonable request.